Continuous oral chloroquine as a novel route for Plasmodium prophylaxis and cure in experimental murine models
© Mueller et al; licensee BioMed Central Ltd. 2011
Received: 24 May 2011
Accepted: 28 July 2011
Published: 28 July 2011
Chloroquine (CQ) is utilized as both cure and prophylaxis to Plasmodium infection. In animal studies, CQ administration to experimental animals is via intraperitoneal (i.p.) injection of a single dose that varies from daily to several times per week. Such daily administration can be distressing to the animals and provoke aggressive behaviors that may affect the immune responses of the animal and interfere with data read-outs.
We describe a novel, viable and efficacious prophylactic and curative administration route whereby chloroquine is continuously supplied in the drinking water to experimental animals. The prophylactic effect is robust and the curative effect against patent blood stage infection comparable to the traditional route of i.p. administration. Continuous drinking water administration may decrease animal stress responses and thus improve the reliability of experimental data.
Chloroquine (CQ) is a classic 4-aminoquinoline that displays rapid schizonticidal activity against the blood stages of many Plasmodium species. Accumulating at high concentrations within the blood-stage digestive vacuole  it forms non-covalent complexes with heme , interferes with heme sequestration to the less toxic product hemozoin and poisons the parasite via the accretion of such drug-heme complexes . Discovered in 1934 and introduced into clinical practise in 1947 as both treatment and primary prophylaxis to malaria disease, it remains the first drug of choice in most sub-Saharan African countries despite the emergence of resistant strains in the late 1950s  harboring the Plasmodium falciparum chloroquine resistance transporter (Pf CRT) gene .
In the laboratory, CQ remains a useful tool, particularly when studying the immunology of murine Plasmodium infection. Since the onset of clinical symptoms are concomitant with the infection of red cells, CQ is often administered as prophylaxis so that the parasite infection manifests within the liver stage but does not develop to blood-stage infection and pathology [6, 7]. The administration of CQ to experimental animals in such studies is in nearly all occasions via intraperitoneal (i.p.) injection of a single dose that varies from daily to several times per week. In large studies, the daily administration of i.p. injections to large-scale-cohorts of mice can be time-consuming, distressing to the animals and provoke aggressive behaviors that may affect the immune responses of the animal and thus interfere with data read-outs [8, 9]. Thus we explored the oral administration route as a prophylactic and curative means of controlling and eliminating Plasmodium berghei ANKA infection in C57BL/6 mice via continuous (and unstopped) administration in the drinking water as a convenient, low-interference administration method.
The water uptake of mice is between 4 and 7 ml per day depending upon air temperature and humidity . Based on this volume we calculated a concentration of CQ salt of 0.288 mg/ml dissolved in normal tap water to deliver a daily oral dose of 1.15 mg to 2.02 mg. This is broadly comparable to the concentrations delivered i.p., which themselves vary from study to study [6, 7]. A small amount of glucose powder (approximately 15 g/l) was dissolved in the CQ solution (hereafter referred to as CQ-DW) to make it more palatable to the animals and encourage consumption. Once dissolved, the solution was administered in tinted light-resistant bottles and refreshed weekly. No other liquid source was available.
Thus CQ-DW offers a convenient and robust method for chloroquine treatment and prophylaxis in experimental murine Plasmodium infection protocols. Over the course of the experiments we did not observe any adverse effects of continuous CQ treatment on the experimental animals. Of additional note is that, unlike pyrimethamine-drinking water preparations that produce a rancid odor and is seemingly associated with a reduction in consumption volumes to minimal levels (unpublished own observations), animals are apparently satisfied to drink CQ-DW, as we observed no change in drinking patterns or habits between normal and CQ-DW administration. Also, it is worth noting that there is a "point of no return" in CQ-DW administration, since in animals with advanced blood-stage infections and such debilitating malarial symptoms that they are incapable of liquid consumption, or show significant lethargy or coma, the nature of "self-administration" of CQ-DW is nullified. Additionally, one inherent limitation to this means of administration is that dosage will vary between individual animals depending upon volume consumed. However, for the purpose of maintaining prophylaxis or curing patent infection, despite potential minor variability in exact dosage, our work demonstrates that CQ-DW administration is efficacious, with robust prophylactic protection and clearance of pre-existing patent parasitemias comparable to the established route of i.p. administration. When considering the applicability of such a method to humans in endemic areas we must be highly cautious, due to considerations such as parasite resistance and the toxic effects associated with CQ treatment [11, 12]. However, despite this, it is conceivable that the administration of individual doses of chloroquine via a dissolving seltzer tablet in water may be a favourable dispensing method over tablets, much like the syrup preparations that are commonly prescribed for infants and young children . Moreover, in the laboratory mouse, it is an efficacious and viable experimental protocol that saves time for the researcher and improves animal welfare standards, perhaps in turn improving the reliability of experimental data.
All animal experiments were performed according to FELASA category B and GV-SOLAS standard guidelines. Animal experiments were approved by German authorities (Regierungspräsidium Karlsruhe, Germany), § 8 Abs. 1 Tierschutzgesetz (TierSchG).
List of abbreviations used
Drinking water supplemented with chloroquine.
We thank Thomas Jänisch and members of the IBF Heidelberg for discussions. We gratefully acknowledge support from the Heidelberg University School of Medicine and the German Federal Ministry of Economy and Technology (BMWI, Exist-Forschungstransfer).
- Yayon A, Cabantchik ZI, Ginsburg H: Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc Natl Acad Sci USA. 1985, 82: 2784-2788. 10.1073/pnas.82.9.2784.PubMedPubMed CentralView ArticleGoogle Scholar
- Chou AC, Chevli R, Fitch CD: Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry. 1980, 19: 1543-1549. 10.1021/bi00549a600.PubMedView ArticleGoogle Scholar
- Orjih AU, Ryerse JS, Fitch CD: Hemoglobin catabolism and the killing of intraerythrocytic Plasmodium falciparum by chloroquine. Experientia. 1994, 50: 34-39. 10.1007/BF01992046.PubMedView ArticleGoogle Scholar
- Payne D: Spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today. 1987, 3: 241-246. 10.1016/0169-4758(87)90147-5.PubMedView ArticleGoogle Scholar
- Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000, 6: 861-871. 10.1016/S1097-2765(05)00077-8.PubMedPubMed CentralView ArticleGoogle Scholar
- Beaudoin RL, Strome CPA, Mitchell F, Tubergen TA: Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol. 1977, 42: 1-5. 10.1016/0014-4894(77)90054-6.PubMedView ArticleGoogle Scholar
- Belnoue E, Costa FTM, Frankenberg T, Vigario AM, Voza T, Leroy N, et al: Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol. 2004, 172: 2487-95.PubMedView ArticleGoogle Scholar
- Esterling B, Rabin BS: Stress-induced alteration of T-lymphocyte subsets and humoral immunity in mice. Behavioral Neuroscience. 1987, 4: 115-119.View ArticleGoogle Scholar
- Borysenko M, Borysenko J: Stress, behavior and immunity: Animal models and mediating mechanisms. General Hospital Psychiatry. 1982, 82: 90028-7.Google Scholar
- Weiss J, Maess J, Nebendahl K, Rossbach W: Haus- und Versuchtierpflege. 1996, Fischer- VerlagGoogle Scholar
- Hobbs HE, Sorsby A, Freedman A: Retinopathy following chloroquine therapy. Lancet. 1959, 2: 478-480.PubMedView ArticleGoogle Scholar
- Bernstein HN, Ginsberg J: The pathology of chloroquine retinopathy. Arch Opthalmol. 1964, 71: 238-245.View ArticleGoogle Scholar
- Ansah EK, Gyapong JO, Agyepong IA, Evans DB: Improving adherence to malaria treatment for children: the use of pre-packed chloroquine tablets vs chloroquine syrup. Trop Med Int Health. 2001, 6 (7): 496-504. 10.1046/j.1365-3156.2001.00740.x.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.